about
Complications of haemophilia in babies (first two years of life): a report from the Centers for Disease Control and Prevention Universal Data Collection System.Current and evolving features in the clinical management of haemophiliaHemophilia Care in the Pediatric Age.Recombinant FIXFc: a novel therapy for the royal disease?The risk associated with indwelling catheters in children with haemophilia.Barriers to primary prophylaxis in haemophilic children: the issue of the venous access.Consensus recommendations for use of central venous access devices in haemophilia.Central venous access devices in patients with hemophilia.Immune tolerance: critical issues of factor dose, purity and treatment complications.Overview of the use of implantable venous access devices in the management of children with inherited bleeding disorders.International workshop on immune tolerance induction: consensus recommendations.Optimizing outcomes for patients with severe haemophilia A.Safety of human plasma-derived clotting factor products and their role in haemostasis in patients with haemophilia: meeting report.Tissue plasminogen activator to prevent central venous access device infections: a systematic review of central venous access catheter thrombosis, infection and thromboprophylaxis.Implantable central venous access device procedures in haemophilia patients without an inhibitor: systematic review of the literature and institutional experience.Improved treatment feasibility in children with hemophilia using arteriovenous fistulae: the results after seven years of follow-up.Novel drugs to treat hemophilia.Pathophysiology, diagnosis and prevention of arthropathy in patients with haemophilia.When should prophylaxis therapy in inhibitor patients be considered?Pharmacotherapy of haemophilia A.Exploring the biological basis of haemophilic joint disease: experimental studies.Endothelial progenitor cell-based therapy for hemophilia A.How to manage invasive procedures in children with haemophilia.Central venous access device-related infections in patients with haemophilia.Renal diseases in haemophilic patients: pathogenesis and clinical management.Development of long-acting recombinant FVIII and FIX Fc fusion proteins for the management of hemophilia.Considerations in individualizing prophylaxis in patients with haemophilia A.Factor VIII therapy for hemophilia A: current and future issues.The role of Rixubis™ in the treatment of hemophilia B.Current management of the hemophilic child: a demanding interlocutor. Quality of life and adequate cost-efficacy analysis.Prevention of bleeding in hemophilia patients with high-titer inhibitors.Central venous access device (CVAD) complications in Haemophilia with inhibitors undergoing immune tolerance induction: Lessons from the international immune tolerance study.Updated analysis: central venous access device infection rates in an expanded cohort of paediatric patients with severe haemophilia receiving prophylactic recombinant tissue plasminogen activator.The impact of clinical practice on the outcome of central venous access devices in children with haemophilia.New findings on inhibitor development: from registries to clinical studies.Central Line Associated Blood Stream Infections in Pediatric Hematology/Oncology Patients With Different Types of Central Lines.The use of short-term central venous catheters for optimizing continuous infusion of coagulation factor concentrate in haemophilia patients undergoing major surgical procedures.Experience with central venous access devices (CVADs) in the Canadian hemophilia primary prophylaxis study (CHPS).Complications associated with central venous access device in children with haemophilia: a nationwide multicentre study in Finland.Long-term follow-up of children with haemophilia - low incidence of infections with central venous access devices.
P2860
Q31140912-A64FB533-6070-4E4A-BCFE-629E055B6D4BQ33708976-9C891ACD-C1E6-4C95-8EE0-5B6506BE0D06Q33737259-B6EFCC22-B5C7-4992-AA5F-65E0C3F0DAF3Q33968782-4817D391-4411-46F4-BBB3-C025F968276BQ34660967-5A13250A-FD98-4D8B-959D-30D1A51D5AABQ34910120-20AA1854-E73C-4688-A9DA-A3395BB5B499Q35882783-0FB9A938-7440-4D09-84D8-7E7C30553722Q36315174-F206AFBB-3DBE-41B7-9FBE-5FE65CA4252AQ36661848-E3FB2CAE-9A35-4D4E-BC79-6B52F9F635B3Q36661853-ECD7FF13-769A-47FB-8FE8-D2D7B2C0D4E2Q36861097-AB0E8EA7-F63C-47A7-B8BB-628E45E99424Q36932769-045A1731-8226-4114-B5C6-292943CBAF8CQ36945970-55B56D9E-A6D5-46D1-A5FB-2D61543F00CBQ37001590-76090DF2-3831-4AEE-A0FF-1EA6A11E796DQ37052161-A9AD13B0-F0B9-45C7-9D04-5B14999119DAQ37175598-AB79791E-0CB5-45AB-BF43-F4F6AE6BAFACQ37775029-688901CA-74B4-46E6-985A-76E16735C456Q37845930-9A2233C2-59A3-4D18-870B-33FF8FA99104Q37854874-9DC0A052-6264-433F-BD9B-21A51CB1B409Q37891089-3A0CD92C-C7FC-4C41-80BA-1F522A4F5430Q37951686-74B4ED53-8523-4BF7-8B8F-2C264512989AQ37982239-FDD2A713-E45E-4C20-B31E-029F19394090Q37990524-2A203F04-75AF-42F6-8DAC-D68F42959DCBQ38084355-E1080E42-0AF0-459F-9DBF-C0CF05AB6CA5Q38104767-3A3CA6A3-159B-42BF-9CE8-99BE3487CC52Q38127745-544105DC-901E-4937-AB02-57C1CFB5A1BAQ38203021-08C4AF88-BDB4-40ED-812A-FA58DD5E5A3AQ38203350-06988814-1037-4214-9CD9-D065C819F7A3Q38210808-8D00C4AD-FE21-4A16-B1B7-4638D7074F9BQ38227605-AC8015B8-9EB4-4023-BC33-9518708E7731Q38456352-5FC9B837-B069-4AF3-8EA4-2664114B368BQ38547840-E6F3C8FC-D637-40FD-987B-2B20A042B9BDQ38561882-A4E0D2AF-8277-403C-A0BE-3EC328BBA838Q38764085-17CE6C29-7434-4FB3-978D-79D36A09517BQ39042987-BAAD9EAA-66ED-4B11-A25E-E25B956B9A6BQ40666855-C0D10F0B-0665-498C-A90F-34F1702FCB37Q40930823-4173694D-C6F6-47DD-8E0E-D996187F2986Q41143756-11044EF5-89E4-4888-9EA6-3172AFD85DB8Q41363389-C4506059-A5DF-42E6-B655-EEA63B382BA8Q41520590-376AA742-2F81-42B7-9CBB-7DCE79181AEF
P2860
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Central venous access devices in haemophilia.
@ast
Central venous access devices in haemophilia.
@en
type
label
Central venous access devices in haemophilia.
@ast
Central venous access devices in haemophilia.
@en
prefLabel
Central venous access devices in haemophilia.
@ast
Central venous access devices in haemophilia.
@en
P2093
P2860
P1433
P1476
Central venous access devices in haemophilia.
@en
P2093
Ewenstein B
Navickis RJ
Valentino LA
P2860
P304
P356
10.1046/J.1365-2516.2003.00840.X
P577
2004-03-01T00:00:00Z